How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

11,127 results for

Headache in Pregnancy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

5081. Intravenous Metoclopramide in the Acute Treatment of Migraine: A Double-blind, Randomized, Placebo-controlled Trial

and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Presenting to the emergency department with migraine attack (with aura or without aura, according to International Headache Society criteria, 2013) The patients older than 18 years Patients who agree to participate to the study by reading and signing the informed consent document Exclusion Criteria: The patients younger than 18 years Pregnants Patients taking any analgesic drugs last (...) Posted: December 11, 2014 Last Update Posted: January 4, 2017 Last Verified: January 2017 Keywords provided by Nurettin Özgür Doğan, Kocaeli University: migraine disorders migraine with aura migraine without aura pain management emergency department Additional relevant MeSH terms: Layout table for MeSH terms Migraine Disorders Headache Disorders, Primary Headache Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Fentanyl Metoclopramide Analgesics, Opioid Narcotics

2014 Clinical Trials

5082. Bevacizumab Therapy for Brain Arteriovenous Malformation

a history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrollment Patients must not have serious, non-healing wound, ulcer, or bone fracture Patients must not be pregnant or breast-feeding. Women of childbearing potential are required to obtain a negative pregnancy test within 14 days of starting treatment. Effective contraception (men and women) must be used in subjects of child-bearing potential Patients must not be on any other (...) , refractory headaches and seizures; for HHT patients, bAVM may be asymptomatic, but patient must have one progressively symptomatic manifestation of HHT that is referable to a vascular lesion, e.g., epistaxis, GI bleeding; or another solid organ AVM Patients must have adequate bone marrow function (WBC > 3,000/μl, ANC > 1,500/mm3, platelet count of > 100,000/mm3, and hemoglobin > 10 mg/dl), adequate liver function (SGOT and bilirubin < 1.5 times ULN), and adequate renal function (creatinine < 1.5 mg/dL

2014 Clinical Trials

5083. Outpatient Medical Abortion With Mifepristone and Misoprostol Through 77 Days of Gestation

(suction curettage or D&C) for any reason Secondary Outcome Measures : Proportion of Individual Side Effects Experienced by Participants [ Time Frame: 7-14 days ] Side effects include diarrhea, nausea, vomiting, fever, chills, headaches, dizziness and/or weakness experienced by participants Proportion of Women Who Determine Method Acceptable [ Time Frame: 7-14 days ] overall acceptability, time to complete abortion, bleeding, side effects, pain Proportion of Providers Who Determine Method Acceptable (...) Resource links provided by the National Library of Medicine available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: 71-77 days gestational age Women whose pregnancies are estimated to have a gestational age of 71-77 days. Drug: Mifepristone followed by misoprostol 24-48 hours later 200mg oral mifepristone and 800mcg buccal misoprostol 24-48 hours after mifepristone No Intervention: 64-70 days gestational age Women whose pregnancies are estimated to have a gestational age

2014 Clinical Trials

5084. Evaluation of Pharmacokinetic and Pharmacodynamic Properties of Intravenous Colistimethate Sodium

, expected to be 2-4 weeks) ] Nephrotoxicity defined as either 1) a rise in serum creatinine (SCr) > or = 0.5 mg/dl; 2) 50% increase in SCr or 3) 25% decrease in estimated creatinine clearance Other Outcome Measures: Number of patients experiencing neurotoxicity [ Time Frame: Baseline, during colistin therapy course (expected to be approximately 14 days), and until hospital discharge (participants will be followed for the duration of hospital stay, expected to be 2-4 weeks) ] Neurotoxicity (headache (...) colistimethate sodium for the treatment of infection Have cystic fibrosis and/or are critically ill (admitted to a critical care unit) Exclusion Criteria: Pregnancy Breastfeeding Prisoners Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02288429 Locations

2014 Clinical Trials

5085. Evaluation of 4D-contrast Enhanced PET-CT in Tumour Volume Definition

contrast media Poorly controlled diabetes Acute renal failure or moderate renal impairment (estimated glomerular filtration rate < 30 mL/min) Claustrophobia precluding imaging Uncontrolled pain Urinary incontinence Female patients must not be pregnant and if of child bearing age using adequate contraception Breast feeding Serious psychiatric comorbidity Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study (...) of radiotherapy of curative intent with or without concurrent chemotherapy Measurable primary tumour and/or locoregional metastatic lymph nodes on preradiotherapy imaging Able to provide fully informed written consent Able to lie flat for 1 hour Not be pregnant or breast feeding. Female patients of childbearing potential must agree to use effective contraception, be surgically sterile, or be postmenopausal. Exclusion Criteria: Hypersensitivity to Fluorine18 fludeoxyglucose (FDG) Hypersensitivity to iodinated

2014 Clinical Trials

5086. Clinical Trial to Determine the Bioavailability of Three Different Zinc Preparations

Vegetarians / vegans Drug-, alcohol- and medication abuses Known HIV-infection Known acute or chronic hepatitis B and C infection Relevant allergy or known hypersensitivity against compounds of the study preparations, for example lactose intolerance Known pregnancy, breast feeding or intention to become pregnant during the study Participation in another clinical trial within the last 4 weeks and concurrent participation in another clinical trial Not anticipating any planned changes in lifestyle (...) or presence of any medical disorder, potentially interfering with this trial For this trial clinically relevant abnormal laboratory, ECG, vital signs or physical findings at screening Migraine or regular headache, intense premenstrual symptoms Coffee consumption >3 cups / day Blood donation within 2 months prior to trial start or during trial Regular intake of mineral supplements within 4 weeks prior to trial start or during trial Chronic intake of substances affecting the intestinal absorption of zinc

2014 Clinical Trials

5087. Talar Avascular Necrosis: Surgical Angiogenesis vs. Core Decompression

the drill holes with the bone graft can lead to reperfusion of the talus. A new technique is to fill the drill hole with a vascularized bone graft from the medial femoral condyle, using microvascular anastomosis. This procedure has already been approved for the treatment of avascular necrosis and malperfusion of the carpus (lunate and scaphoid) as well as the femoral head. Patients are examined preoperative as well as 3, 6 and 12 month after operation, documenting the active range of motion and pain (...) Patients in this arm receive core decompression followed by osseous autograft from the iliac crest Procedure: core decompression retrograd drilling of the avascular talar necrosis, followed by osseous autograft Outcome Measures Go to Primary Outcome Measures : Pain reduction [ Time Frame: 3, 6, 12 months post operation ] Secondary Outcome Measures : Lower Extremity Functional Scale [ Time Frame: pre operation; 3, 6, 12 month post operation ] Revascularization (Association International de Recherche sur

2014 Clinical Trials

5088. Placebo-Controlled Evaluation of Intranasal Dexmedetomidine for Postoperative Analgesia Following Bunionectomy Surgery

medications used in this study. Have a clinically significant abnormal clinical laboratory test value. Have history of or positive test results for HIV, or hepatitis B or C. Have a history or clinical manifestations of significant renal, hepatic, cardiovascular, metabolic, neurologic, psychiatric, or other condition that would preclude participation in the study. Have a history of migraine or frequent headaches, seizures, or are currently taking anticonvulsants. Have another painful physical condition (...) Posted : November 5, 2014 Results First Posted : May 2, 2017 Last Update Posted : May 2, 2017 Sponsor: Recro Pharma, Inc. Collaborator: Lotus Clinical Research, LLC Information provided by (Responsible Party): Recro Pharma, Inc. Study Details Study Description Go to Brief Summary: The primary objective of this study is to evaluate the analgesic efficacy, on Post-Operative Day (POD) 1, of DEX-IN compared with placebo, using the summed pain intensity difference over the first 48 hours (SPID48

2014 Clinical Trials

5089. Atenativ Effect on Uterine Blood Flow and Preeclampsia

/90 and proteinuria >0.3 g/24 h) with IUGR or subjective symptoms as epigastic pain (HELLP), headache, dizziness or visual disturbancies, oligouri < 600 ml/24 h, coagulation disturbancies. AT level <0.8 kIE/L Exclusion Criteria:1. History of congenital AT deficiency 2. Severe preeclampsia with demand on acute delivery within 24 hours according to the investigators judgments 3. Concomitant administration of anticoagulants and platelet inhibitors within 2 weeks 4. Chronic renal disease 5. Diabetes (...) : Blood flow in uterin and umbilical artery [ Time Frame: up to day 14 ] Secondary Outcome Measures : fetal outcome [ Time Frame: at birth ] CTG, blood flow, Apgar score, birthweight bleeding complications [ Time Frame: during pregnancy and at delivery ] measurements of bleeding before and after placenta delivery Other Outcome Measures: Biomarkers of endothelial damage [ Time Frame: up to day 14 ] S-Flt-1, VEGF,Syndecan-1 Atenativ concentrate [ Time Frame: treatment during 2 weeks ] amount needed

2014 Clinical Trials

5090. Motor Cortex as a Research & Therapeutic Target in TMD

, a modular EEG recording cap will be placed on the subject's head and the anodal electrode will be placed on the motor cortex contralateral to the worst TMD pain side (C3). Current will be applied only for 30 seconds - this is a reliable method of sham stimulation (Gandiga et al., 2006) as sensations arising from tDCS treatment occur only at the beginning of application. Device: High-Definition Transcranial Direct Current Stimulation (HD-tDCS) HD-tDCS is a non-invasive brain neuromodulatory method for M1 (...) that involves sending a weak electrical current into your brain. Experimental: Experimental The subjects in the experimental arm will participate in 5 daily sessions. During each session, a modular EEG recording cap will be placed on the subject's head and the anodal electrode will be placed on the motor cortex contralateral to the worst TMD pain side (C3). Then 2mA of transcranial direct current stimulation will be applied for 20 minutes. Device: High-Definition Transcranial Direct Current Stimulation (HD

2014 Clinical Trials

5091. The Effect of Paracetamol, Pseudoephedrine Hydrochloride, Dextromethorphan Hydrobromide and Chlorpheniramine Maleate Tablets Compared to Placebo in Subjects Suffering From the Common Cold or Influenza.

Participants diagnosed with a common cold or flu and must have the following symptoms of at least "moderate" in intensity (≥ 2) at the screening visit (baseline), with a minimum total symptom score of 6: (i) At least one of pain symptoms: sore throat, headache, or extremities pain (ii) Mandatory: Nasal congestion (iii) At least one of catarrh symptoms: runny nose or sneezing Onset of first symptoms of cold must have occurred within 48 hours of screening. Exclusion Criteria: Pregnant or breast feeding women (...) measure. TSS was calculated as the sum of the non missing scores (all on a 0-3 scale measuring worsening or severity) of the following common cold symptoms: sore throat, headache, extremities pain, nasal congestion, runny nose, sneezing, and cough post treatment administration. Participants self assessed symptoms severity using 4 points (0 = absent, 1 = mild, 2 = moderate, and 3 = severe) categorical scale at 15 minutes post product use. Symptom Severity Assessment at 30 Minutes [ Time Frame: 30

2014 Clinical Trials

5092. Stem Cell Gene Therapy for Sickle Cell Disease

blood CD34+ cells Phase 1 Phase 2 Detailed Description: Sickle cell disease (SCD) affects ~90,000 people in the U.S. who suffer significant neurological, lung, and kidney damage, as well as severe chronic pain episodes that adversely impact on quality of life. While current medical therapies for SCD can reduce short-term morbidity, the inevitable progressive deterioration in organ function results in a significant decrease in quality of health with early mortality. Allogeneic hematopoietic stem cell (...) Diagnosis of SCD documented by phenotype (Hb electrophoresis) or genetic analysis (S/S, S/β-thalassemia-zero) Must not have medically eligible and available HLA-identical sibling donor or 10/10 allele-matched unrelated donor Inadequate clinical response to hydroxyurea (HU), defined as any one of the following outcomes, while on HU for at least 3 months: 2 or more acute sickle pain crises requiring hospitalization no rise in Hb >1.5 gm/dl from pre-HU baseline or requires transfusion to maintain Hb > 6.0

2014 Clinical Trials

5093. Controlled Acute Hypoxia Study Comparing Pulse Oximetry to Arterial Blood Samples During Motion

information, Layout table for eligibility information Ages Eligible for Study: 18 Years to 50 Years (Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: Yes Criteria Inclusion Criteria: Male or female of any race 18-50 years old, inclusive Females: negative urine pregnancy test on the day of study participation (prior to exposure to hypoxia) Completed within the last year: physical exam by a licensed physician, physician assistant (PA), or advanced practice nurse; including a 12 lead ECG (...) , a medical history, and blood test (complete blood count and sickle cell trait/disease screening) Meets specific demographic requirements for the monitoring device under study Willing and able to provide written informed consent Able to participate for the duration of the evaluation Exclusion Criteria: A room-air baseline % modulation < 1.5% on all four fingers on the test hand Under 18 years or over 50 years of age Pregnant and/or lactating women Hypertension: on three consecutive readings, systolic

2014 Clinical Trials

5094. Prospective Clinical 5-year Follow-up of the LINK® SP-CL® Hip Prosthesis Stem

be used for future regulatory processes if needed. Condition or disease Osteoarthritis, Hip Femur Head Necrosis Femoral Neck Fractures Detailed Description: Post Market Clinical Follow-ups (PMCF) through observational studies are an important tool to detect infrequent complications or problems, events specific to defined patient populations and long term performance issues under routine conditions [2,3]. Against this background a prospective multi-center outcome study of the LINK® SP-CL® is planned (...) and Cohorts Go to Outcome Measures Go to Primary Outcome Measures : Stem Survival Rate [ Time Frame: Up to 5 years ] The survival of the stem Secondary Outcome Measures : Complication Rate [ Time Frame: Up to 5 years ] Number and kind of complications Reoperation Rate [ Time Frame: Up to 5 years ] number of reoperations Harris Hip Score (HHS) [ Time Frame: Up to 5 years ] Clinical Score to get information about the subjects pain and hip function, collected continuously Oxford Hip Score (OHS) [ Time Frame

2014 Clinical Trials

5095. Recombinant Human Endostatin Adenovirus Combined With Chemotherapy for Advanced Head and Neck Malignant Tumors

Recombinant Human Endostatin Adenovirus Combined With Chemotherapy for Advanced Head and Neck Malignant Tumors Recombinant Human Endostatin Adenovirus Combined With Chemotherapy for Advanced Head and Neck Malignant Tumors - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved (...) studies (100). Please remove one or more studies before adding more. Recombinant Human Endostatin Adenovirus Combined With Chemotherapy for Advanced Head and Neck Malignant Tumors The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02283489 Recruitment Status : Unknown Verified November 2014 by Renmiao

2014 Clinical Trials

5096. Radiofrequency Ablation vs Laser Ablation of the Incompetent Greater Saphenous Vein

Insufficiency Procedure: Ablation of the Incompetent Greater Saphenous Vein Device: ClosureFAST radiofrequency catheter Device: EVLT 980nm diode laser system Phase 4 Detailed Description: Chronic venous insufficiency (CVI) is estimated to affect 25 million Americans. This condition leads to varicose veins, aching, fatigue, swelling, ulcerations, and bleeding in the lower extremities. The most common cause is a refluxing or incompetent Greater Saphenous Vein (GSV). This condition results in pooling (...) or radiofrequency probe through the catheter. These devices then produce the energy to destroy the vein as the catheters are slowly pulled back. While both radiofrequency ablation and laser ablation are accepted treatments, neither technology has been definitively proved to have fewer complications or superior results. This is in part because very few practices have the ability to make a head to head comparison between the two technologies and must choose one or the other secondary to financial constraints

2014 Clinical Trials

5097. Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain Stimulation

(particularly the head in the stereotactic frame), stress related to the localization of the DBS. It is therefore important to improve the comfort as well as the cooperation of the patient, during implantation of the DBS electrodes, in order to optimize the conditions of the intervention. In addition to analgesia, acupuncture should allow sedation without affecting alertness and should contribute to the regulation of any vegetative reactions during the procedure. Therefore, we hypothesize that acupuncture (...) Date : June 12, 2017 Actual Study Completion Date : June 14, 2017 Resource links provided by the National Library of Medicine related topics: related topics: Arms and Interventions Go to Arm Intervention/treatment Active Comparator: Local anesthesia alone Drug: Local Anesthesia (lidocaine hydrochloride) All patients will receive injectable paracetamol for pain relief, a mix of nitrous oxide 50% and oxygen 50% for analgesia and lidocaine hydrochloride for local anesthesia. Experimental: Local

2014 Clinical Trials

5098. Anti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy

, purulence in nasal cavity, or impaired or loss of smell. Minor factors are defined as headache, fever, halitosis, fatigue, dental pain, cough, and ear pain, pressure, or fullness. History of systemic disease affecting the immune system such as autoimmune diseases, immune complex disease, or immunodeficiency, where, in the opinion of the study physician, participation in the trial would pose a risk or significant effect on the immune system Diabetes (Type I or II) Evidence of any active or suspected (...) for asthma in the previous 12 months History of chronic obstructive pulmonary disease (COPD) History of significant recurrent acute sinusitis, defined as 2 episodes/yr for the last 2 years, all of which required antibiotic treatment History of chronic sinusitis, defined as a sinus symptoms lasting >12 weeks that includes >/=2 major factors or 1 major factor and 2 minor factors. Major factors are defined as facial pain or pressure, nasal obstruction or blockage, purulent or discolored postnasal discharge

2014 Clinical Trials

5099. Development of a Monitoring Set-up and Algorithm Using Functional MRI (fMRI) and EEG for Prediction of Response to Repetitive Deep Transcranial Magnetic Stimulation (rDTMS) for Patients With Parkinson's Disease

with psychotic symptoms or active depressive symptoms Treatment with neuroleptics. Beck depression inventory (BDI) score <14 Mini Mental status examination (MMSE) score <25 History of migraine or frequent or severe headaches. Significant sensory deficits, e.g., deafness or blindness History of head injury or neurosurgical interventions. Subjects who have concomitant epilepsy, a history of seizure/s, heat convulsions or history of epilepsy in first degree relative. History of any metal in the head (outside (...) the mouth). The presence of cochlear implants Known history of any metallic particles in the eye, implanted cardiac pacemaker, implanted neurostimulators, surgical clips (above the shoulder line) or any medical pumps. Subjects with an unstable medical disorder. Current drug abuse (including Cannabis) or alcoholism. Pregnancy or not using a reliable method of birth control. Patients with severe tremor or dyskinesia Contacts and Locations Go to Information from the National Library of Medicine To learn

2014 Clinical Trials

5100. Radiofrequency Ablation vs. Laser Ablation of the Incompetent Small Saphenous Vein

or disease Intervention/treatment Phase Chronic Venous Insufficiency Procedure: Ablation of the incompetent small saphenous vein Phase 4 Detailed Description: Chronic venous insufficiency (CVI) is estimated to affect 25 million Americans. This condition leads to varicose veins, aching, fatigue, swelling, ulcerations, and bleeding in the lower extremities. The second most common cause is a refluxing or incompetent Small Saphenous Vein (SSV). This condition results in pooling of deoxygenated blood (...) the catheter. These devices then produce the energy to destroy the vein as the catheters are slowly pulled back. While both radiofrequency ablation and laser ablation are accepted treatments, neither technology has been definitively proved to have fewer complications or superior results. This is in part because very few practices have the ability to make a head to head comparison between the two technologies and must choose one or the other secondary to financial constraints. The aim of this study

2014 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>